Glucose inhibits the insulin-induced activation of the insulin-degrading enzyme in HepG2 cells

Aims/hypothesisHepatic insulin degradation decreases in type 2 diabetes. Insulin-degrading enzyme (IDE) plays a key role in insulin degradation and its gene is located in a diabetes-associated chromosomal region. We hypothesised that IDE may be regulated by insulin and/or glucose in a liver cell model. To validate the observed regulation of IDE in vivo, we analysed biopsies of human adipose tissue during different clamp experiments in men.MethodsHuman hepatoma HepG2 cells were incubated in normal (1 g/l) or high (4.5 g/l) glucose medium and treated with insulin for 24 h. Catalytic activity, mRNA and protein levels of IDE were assessed. IDE mRNA levels were measured in biopsies of human subcutaneous adipose tissue before and at 240 min of hyperinsulinaemic, euglycaemic and hyperglycaemic clamps.ResultsIn HepG2 cells, insulin increased IDE activity under normal glucose conditions with no change in IDE mRNA or protein levels. Under conditions of high glucose, insulin increased mRNA levels of IDE without changes in IDE activity. Both in normal and high glucose medium, insulin increased levels of the catalytically more active 15a IDE isoform compared with the 15b isoform. In subcutaneous adipose tissue, IDE mRNA levels were not significantly upregulated after euglycaemic or hyperglycaemic clamps.Conclusions/interpretationInsulin increases IDE activity in HepG2 cells in normal but not in high glucose conditions. This disturbance cannot be explained by corresponding alterations in IDE protein levels or IDE splicing. The loss of insulin-induced regulation of IDE activity under hyperglycaemia may contribute to the reduced insulin extraction and peripheral hyperinsulinaemia in type 2 diabetes.

[1]  Matthew P. Frosch,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Eric Verdin,et al.  Regulation of Insulin Secretion by SIRT4, a Mitochondrial ADP-ribosyltransferase* , 2007, Journal of Biological Chemistry.

[3]  M. Folstein,et al.  Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis , 2006, Neurobiology of Aging.

[4]  A. Joachimiak,et al.  Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism , 2006, Nature.

[5]  J. H. Kim,et al.  Association of polymorphisms in the insulin-degrading enzyme gene with type 2 diabetes in the Korean population. , 2008, Diabetes research and clinical practice.

[6]  R. Vigneri,et al.  Defects in Insulin-Receptor Internalization and Processing in Monocytes of Obese Subjects and Obese NIDDM Patients , 1989, Diabetes.

[7]  Joseph B. Rayman,et al.  The Finland-United States investigation of non-insulin-dependent diabetes mellitus genetics (FUSION) study. I. An autosomal genome scan for genes that predispose to type 2 diabetes. , 2000, American journal of human genetics.

[8]  Insulin inhibits the ubiquitin-dependent degrading activity of the 26S proteasome. , 2000, Endocrinology.

[9]  T. Hudson,et al.  A genome-wide association study identifies novel risk loci for type 2 diabetes , 2007, Nature.

[10]  L. Hersh,et al.  Substrate Activation of Insulin-degrading Enzyme (Insulysin) , 2003, Journal of Biological Chemistry.

[11]  W. Duckworth,et al.  An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. , 2003, Diabetes.

[12]  D. Selkoe,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  W. Duckworth,et al.  Insulin inhibits peroxisomal fatty acid oxidation in isolated rat hepatocytes. , 2001, Endocrinology.

[14]  J. Cresto,et al.  Insulin-Degrading Enzyme Hydrolyzes ATP , 2007, Experimental biology and medicine.

[15]  B. Hyman,et al.  Decreased Catalytic Activity of the Insulin-degrading Enzyme in Chromosome 10-Linked Alzheimer Disease Families* , 2007, Journal of Biological Chemistry.

[16]  F. Hamel,et al.  In vitro inhibition of insulin-degrading enzyme by long-chain fatty acids and their coenzyme A thioesters. , 2003, Endocrinology.

[17]  A. Pfeiffer,et al.  Reduced hepatic insulin extraction in response to gastric inhibitory polypeptide compensates for reduced insulin secretion in normal-weight and normal glucose tolerant first-degree relatives of type 2 diabetic patients. , 2004, Diabetes.

[18]  P. T. Varandani,et al.  Insulin-degrading neutral cysteine proteinase activity of adipose tissue and liver of nondiabetic, streptozotocin-diabetic, and insulin-treated diabetic rats. , 1987, Archives of biochemistry and biophysics.

[19]  E. Standl,et al.  Insulin degrading enzyme activity and insulin binding of erythrocytes in normal subjects and Type 2 (non-insulin-dependent) diabetic patients , 1984, Diabetologia.

[20]  J. Janosky,et al.  Hyperinsulinemia in african-american children: decreased insulin clearance and increased insulin secretion and its relationship to insulin sensitivity. , 2002, Diabetes.

[21]  V. Mohan,et al.  Immunoreactive insulin and insulin degrading enzymes in erythrocytes. A preliminary report. , 1990, The Journal of the Association of Physicians of India.

[22]  Jennifer L. Levy,et al.  Regulation of protein degradation by insulin-degrading enzyme: analysis by small interfering RNA-mediated gene silencing. , 2007, Archives of biochemistry and biophysics.

[23]  P. Wilson,et al.  A genome-wide scan for loci linked to plasma levels of glucose and HbA(1c) in a community-based sample of Caucasian pedigrees: The Framingham Offspring Study. , 2002, Diabetes.

[24]  T. Šarić,et al.  Non-covalent interaction of ubiquitin with insulin-degrading enzyme , 2003, Molecular and Cellular Endocrinology.

[25]  E. Bonora,et al.  Decreased hepatic insulin extraction in subjects with mild glucose intolerance. , 1983, Metabolism: clinical and experimental.

[26]  D. Selkoe,et al.  Structural biology: Enzyme target to latch on to , 2006, Nature.

[27]  D. Selkoe,et al.  Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid beta-protein. , 2005, Biochemistry.

[28]  B. Teter,et al.  Insulin-Degrading Enzyme as a Downstream Target of Insulin Receptor Signaling Cascade: Implications for Alzheimer's Disease Intervention , 2004, The Journal of Neuroscience.

[29]  D. Selkoe,et al.  Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. , 2004, The American journal of pathology.

[30]  A. Brookes,et al.  Quantitative trait loci near the insulin-degrading enzyme (IDE) gene contribute to variation in plasma insulin levels. , 2004, Diabetes.

[31]  L. Hersh,et al.  ATP Effects on Insulin-degrading Enzyme Are Mediated Primarily through Its Triphosphate Moiety* , 2004, Journal of Biological Chemistry.

[32]  Mengwei Zang,et al.  AMP-activated Protein Kinase Is Required for the Lipid-lowering Effect of Metformin in Insulin-resistant Human HepG2 Cells* , 2004, Journal of Biological Chemistry.

[33]  D. Selkoe,et al.  Neurons Regulate Extracellular Levels of Amyloid β-Protein via Proteolysis by Insulin-Degrading Enzyme , 2000, The Journal of Neuroscience.

[34]  P. Wilson,et al.  Polymorphisms in the insulin-degrading enzyme gene are associated with type 2 diabetes in men from the NHLBI Framingham Heart Study. , 2003, Diabetes.

[35]  R. Roth,et al.  Overexpression of insulin degrading enzyme: cellular localization and effects on insulin signaling. , 1997, Biochemical and biophysical research communications.

[36]  R. DeFronzo.  Pathogenesis of Type 2 (non-insulin dependent) diabetes mellitus: a balanced overview , 1992, Diabetologia.

[37]  W. Ogawa,et al.  Affinity purification of insulin-degrading enzyme and its endogenous inhibitor from rat liver. , 1992, The Journal of biological chemistry.

[38]  P. Wilson,et al.  A Genome-Wide Scan for Loci Linked to Plasma Levels of Glucose and HbA1c in a Community-Based Sample of Caucasian Pedigrees: The Framingham Offspring Study , 2002 .

[39]  W. Duckworth,et al.  Insulin degradation: progress and potential. , 1998, Endocrine reviews.

[40]  D. Steiner,et al.  The metabolism of proinsulin and insulin by the liver. , 1972, The Journal of clinical investigation.

[41]  F. S. French,et al.  Androgen and glucocorticoid receptors interact with insulin degrading enzyme. , 1994, The Journal of biological chemistry.

[42]  A. Montag,et al.  Insulin-degrading enzyme is differentially expressed and developmentally regulated in various rat tissues. , 1993, Endocrinology.